HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Facebook OKs Supplement Ads, But Leaves Ingredients Off Its Friends List

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement firms posting ads on Facebook should keep in mind that FDA and the Federal Trade Commission are among the social media platform’s more than 750 million users.

You may also be interested in...

Retailers Share Keys To Gaining Shelf Space

The addition next year of quick-response codes to all vitamin and supplement lines at Sam’s Club highlights the importance retailers place on products’ strong social media presence.

Firms Navigate Social Media Safely Following Loss Of Facebook Protection

Several drug companies may have shuttered their Facebook pages prematurely in August after the social networking site revoked their exclusive privilege to block consumer comments on their walls.

U.K. Advertising Watchdog Will Monitor Facebook, Twitter Ads

In March 2011, the U.K.'s Advertising Standards Authority will extend oversight to marketing messages on firms' websites and online social networking space, such as Facebook and Twitter

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts